These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 39189230)

  • 1. Newborn Screening for Spinal Muscular Atrophy: Variations in Practice and Early Management of Infants with Spinal Muscular Atrophy in the United States.
    Zaidman CM; Crockett CD; Wedge E; Tabatabai G; Goedeker N
    Int J Neonatal Screen; 2024 Aug; 10(3):. PubMed ID: 39189230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go.
    Dangouloff T; Vrščaj E; Servais L; Osredkar D;
    Neuromuscul Disord; 2021 Jun; 31(6):574-582. PubMed ID: 33985857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy for spinal muscular atrophy is considerably effective when administered as early as possible after birth.
    Sawada T; Kido J; Yae Y; Yuge K; Nomura K; Okada K; Fujiyama N; Ozasa S; Nakamura K
    Mol Genet Metab Rep; 2023 Jun; 35():100973. PubMed ID: 37091744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy.
    Ke Q; Zhao ZY; Mendell JR; Baker M; Wiley V; Kwon JM; Alfano LN; Connolly AM; Jay C; Polari H; Ciafaloni E; Qi M; Griggs RC; Gatheridge MA
    World J Pediatr; 2019 Jun; 15(3):219-225. PubMed ID: 30904991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variability in Newborn Screening Across Canada: Spinal Muscular Atrophy and Beyond.
    Groulx-Boivin E; Osman H; Chakraborty P; Lintern S; Oskoui M; Selby K; Van Caeseele P; Wyatt A; McMillan HJ
    Can J Neurol Sci; 2024 Mar; 51(2):203-209. PubMed ID: 36892082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spinal Muscular Atrophy Update in Best Practices: Recommendations for Diagnosis Considerations.
    Schroth M; Deans J; Arya K; Castro D; De Vivo DC; Gibbons MA; Ionita C; Kuntz NL; Lakhotia A; Neil Knierbein E; Scoto M; Sejersen T; Servais L; Tian C; Waldrop MA; Vázquez-Costa JF
    Neurol Clin Pract; 2024 Aug; 14(4):e200310. PubMed ID: 38915908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Landscape of Spinal Muscular Atrophy Newborn Screening in the United States: 2018-2021.
    Hale K; Ojodu J; Singh S
    Int J Neonatal Screen; 2021 Jun; 7(3):. PubMed ID: 34202531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of Spinal Muscular Atrophy Based on the Results of a Large-Scale Pilot Project on 202,908 Newborns.
    Efimova IY; Zinchenko RA; Marakhonov AV; Balinova NV; Mikhalchuk KA; Shchagina OA; Polyakov AV; Mudaeva DA; Saydaeva DH; Matulevich SA; Parshintseva PD; Belyashova EY; Yakubovskiy GI; Tebieva IS; Gabisova YV; Irinina NA; Jamschikova AV; Nurgalieva LR; Saifullina EV; Nevmerzhitskaya KS; Belyaeva TI; Romanova OS; Voronin SV; Kutsev SI
    Pediatr Neurol; 2024 Jul; 156():147-154. PubMed ID: 38781723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parental Experiences with Newborn Screening and Gene Replacement Therapy for Spinal Muscular Atrophy.
    Meyer AP; Connolly AM; Vannatta K; Hacker N; Hatfield A; Decipeda A; Parker P; Willoughby A; Waldrop MA
    J Neuromuscul Dis; 2024; 11(1):129-142. PubMed ID: 38160362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newborn screening for spinal muscular atrophy in Osaka -challenges in a Japanese pilot study.
    Kimizu T; Ida S; Oki K; Shima M; Nishimoto S; Nakajima K; Ikeda T; Mogami Y; Yanagihara K; Matsuda K; Nishi E; Hasegawa Y; Nozaki M; Fujita H; Irie A; Katayama T; Okamoto N; Imai K; Nishio H; Suzuki Y
    Brain Dev; 2023 Aug; 45(7):363-371. PubMed ID: 36973114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newborn Screening for Spinal Muscular Atrophy: Ontario Testing and Follow-up Recommendations.
    McMillan HJ; Kernohan KD; Yeh E; Amburgey K; Boyd J; Campbell C; Dowling JJ; Gonorazky H; Marcadier J; Tarnopolsky MA; Vajsar J; MacKenzie A; Chakraborty P
    Can J Neurol Sci; 2021 Jul; 48(4):504-511. PubMed ID: 33059774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case report: A case of spinal muscular atrophy in a preterm infant: risks and benefits of treatment.
    Nigro E; Grunebaum E; Kamath B; Licht C; Malcolmson C; Jeewa A; Campbell C; McMillan H; Chakraborty P; Tarnopolsky M; Gonorazky H
    Front Neurol; 2023; 14():1230889. PubMed ID: 37780708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
    Day JW; Finkel RS; Chiriboga CA; Connolly AM; Crawford TO; Darras BT; Iannaccone ST; Kuntz NL; Peña LDM; Shieh PB; Smith EC; Kwon JM; Zaidman CM; Schultz M; Feltner DE; Tauscher-Wisniewski S; Ouyang H; Chand DH; Sproule DM; Macek TA; Mendell JR
    Lancet Neurol; 2021 Apr; 20(4):284-293. PubMed ID: 33743238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The implementation of newborn screening for spinal muscular atrophy: the Australian experience.
    Kariyawasam DST; Russell JS; Wiley V; Alexander IE; Farrar MA
    Genet Med; 2020 Mar; 22(3):557-565. PubMed ID: 31607747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onasemnogene abeparvovec-xioi: a gene replacement strategy for the treatment of infants diagnosed with spinal muscular atrophy.
    Schwartz M; Likhite S; Meyer K
    Drugs Today (Barc); 2021 Jun; 57(6):387-399. PubMed ID: 34151905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Barriers to Referral and Appointment Wait Times for the Evaluation of Spinal Muscular Atrophy (SMA): Findings from a Web-Based Physician Survey.
    Curry MA; Cruz RE; Belter LT; Schroth MK; Jarecki J
    Neurol Ther; 2024 Jun; 13(3):583-598. PubMed ID: 38430355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newborn screening for spinal muscular atrophy in Japan: One year of experience.
    Sawada T; Kido J; Sugawara K; Yoshida S; Ozasa S; Nomura K; Okada K; Fujiyama N; Nakamura K
    Mol Genet Metab Rep; 2022 Sep; 32():100908. PubMed ID: 35942129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England.
    Weidlich D; Servais L; Kausar I; Howells R; Bischof M
    Neurol Ther; 2023 Aug; 12(4):1205-1220. PubMed ID: 37222861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating newborn screening for spinal muscular atrophy into health care systems: an Australian pilot programme.
    D'Silva AM; Kariyawasam DST; Best S; Wiley V; Farrar MA;
    Dev Med Child Neurol; 2022 May; 64(5):625-632. PubMed ID: 34839535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spinal Muscular Atrophy: Diagnosis, Incidence, and Newborn Screening in Japan.
    Kimizu T; Ida S; Okamoto K; Awano H; Niba ETE; Wijaya YOS; Okazaki S; Shimomura H; Lee T; Tominaga K; Nabatame S; Saito T; Hamazaki T; Sakai N; Saito K; Shintaku H; Nozu K; Takeshima Y; Iijima K; Nishio H; Shinohara M
    Int J Neonatal Screen; 2021 Jul; 7(3):. PubMed ID: 34287247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.